Healthy
Conditions
Brief summary
The present study will seek to quantify the muscle protein synthetic response to a protein beverage consumed orally or through a nasogastric tube in healthy, young individuals.
Detailed description
Thirty healthy, young volunteers will receive a stable isotope tracer infusion (8.5h) combined with repeated blood and muscle sampling, in order to measure muscle protein synthesis rate in the postabsorptive state, and following oral placebo ingestion (n=10), oral protein ingestion (n=10), or enteral protein administration (n=10).
Interventions
OTHEROral Placebo
A placebo beverage will be consumed orally
OTHEROral Protein
A protein beverage will be consumed orally
OTHEREnteral Protein
A protein beverage will be consumed via a naso-gastric feeding tube
Sponsors
University of Exeter
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Masking description
Oral conditions are double blinded to participant and investigator, but enteral vs oral feeding is not blinded
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* 18-40 years of age * Body mass index between 18.5 and 30
Exclusion criteria
* Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes) * Any diagnosed cardiovascular disease * Elevated blood pressure at the time of screening. (An average systolic blood pressure reading of ≥140 mmHg over two or more measurements and an average diastolic blood pressure of ≥90 mmHg over two or more measurements) * Chronic use of any prescribed or over the counter pharmaceuticals (that may modulate muscle protein metabolism). This excludes oral contraceptives and contraceptive devices. * A personal or family history of epilepsy, seizures or schizophrenia. * Presence of an ulcer in the stomach or gut and/or strong history of indigestion * Known pre-existing liver disease/condition * Any known disorders in muscle metabolism * Regular use of nutritional supplements * Allergy to lidocaine * Allergy to milk * Current paracetamol use (i.e. use of paracetamol more than once a week) * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postprandial muscle protein synthesis | 5 hours | Muscle protein synthesis rate (FSR) following ingestion of a placebo or protein supplement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Whole-body protein synthesis | 7 hours | Whole-body protein synthesis, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h) |
| Whole-body protein breakdown | 7 hours | Whole-body protein breakdown, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h) |
| Whole-body protein oxidation | 7 hours | Whole-body protein oxidation, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h) |
| Postabsorptive muscle protein synthesis | 2 hours | Muscle protein synthesis rate (FSR, in %/h) during a 2 hour fasting period |
| Gastric emptying rate | 5 hours | Gastric emptying rate following ingestion of a placebo or protein drink |
| Blood glucose concentration | 8.5 hours | Blood glucose concentration in the postabsorptive and postprandial phase following placebo/protein ingestion |
| Serum insulin concentration | 8.5 hours | Serum insulin concentration in the postabsorptive and postprandial phase following placebo/protein ingestion |
| Whole-body protein net balance | 7 hours | Whole-body protein net balance, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h) |
Countries
United Kingdom
Outcome results
None listed